Solventum Corporation reported a leadership change in its finance organization, announcing that its board of directors appointed Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer. The appointment was made on July 16, 2026, and will become effective August 10, 2026. Zieselman will replace Mary Wilcox in the role in connection with her previously announced retirement. He will report directly to Wayde McMillan, Solventum’s Chief Financial Officer, and will serve as the company’s Principal Accounting Officer for SEC reporting purposes. The disclosure was made under Item 5.02 of Form 8-K, which covers changes involving directors, certain officers and compensatory arrangements. Zieselman, 50, joins Solventum from Surgery Partners, Inc., where he had served as Senior Vice President, Corporate Finance and Controller since May 2022. Before that, he held several finance leadership roles at Stryker Corporation, including Vice President, Finance Operations from April 2021 to May 2022, Senior Director, Finance Transformation from August 2019 to April 2021, and Senior Director, Finance and Group Controller for the Orthopaedics Group from January 2017 to August 2019. Earlier in his career, he held accounting and finance leadership positions at Covanta Holding Corporation, including Vice President and Chief Accounting Officer, as well as roles at Cendant Corporation and Avaya Inc. He began his career as an auditor at PricewaterhouseCoopers LLP. Zieselman is a licensed CPA and holds a Bachelor of Science degree in Accounting from Rider University, where he graduated summa cum laude. In connection with the appointment, Solventum said Zieselman’s compensation will include an annual base salary that is “materially consistent” with the scope of the role and his experience, plus a target annual bonus equal to 50% of base salary, subject to his employment on the applicable payment date. He will also be eligible for an annual long-term incentive target award of $500,000. Solventum also agreed to provide Zieselman with a $130,000 cash sign-on bonus and an initial $600,000 grant of restricted stock units. The RSUs will vest in three equal installments on the first three anniversaries of the grant date, contingent on continued employment. The filing did not disclose the number of shares underlying the RSU award or any grant-date share price. As a result of the appointment, Zieselman will also be eligible to participate in the Solventum Executive Severance Plan. The company stated that Zieselman’s appointment was not made pursuant to any agreement or understanding with another person. Solventum also disclosed that he has no family relationship with any director or executive officer of the company and that there are no related-party transactions involving Zieselman requiring disclosure under Item 404(a) of Regulation S-K.